Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2021

View Archived Issues

Potent selective pan-serotype dengue inhibitor developed

Discovery and preclinical characterization of novel TLR3 agonist, TL-532

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent ADCs including B7-H3 antibodies

New NLRP3 inflammasome inhibitors identified at Astellas Pharma

Atux Iskay presents new anticancer compounds

New TRK inhibitors divulged by J2H Biotech

Preclinical data presented for RP-3500

NVL-520 demonstrates efficacy in PDX models harboring ROS1 fusions

Regeneration of GABAergic neurons by in vivo reprogramming of glial cells reduces epileptic seizures

BRD9 is a druggable target for treating ccRCC with absent or low HIF-2alpha expression

ENPP1 inhibitor TXN-10128 shows promising antitumor activity trough restoration of STING activation

AavantiBio expands partnership with University of Florida to create gene therapy capsids

Creative Medical Technology announces proof-of-concept data on ImmCelz immunotherapy product

Hereditary Neuropathy Foundation and Rarebase partner to find treatments for Charcot-Marie Tooth

Poseida and Takeda partner on nonviral in vivo gene therapy programs

Amydis receives NINDS funding to explore presence of ASYN in retina of Parkinson's models

Kallistatin is a marker of NAFLD progression in patients with hypertension

NV-CoV-2 effective against SARS-CoV-2 in standard cell culture pseudovirion assay

Liver TR-beta1 activation can alleviate nonalcoholic steatohepatitis

NCI grant supports development of ST-316 to treat Wnt/beta-catenin-dependent breast cancer

Preclinical data support use of ibrexafungerp to treat mucormycosis

Emmaus gains license to Kainos' novel IRAK-4 inhibitor KM-10544

BridgeBio reports highlights from preclinical cancer and gene therapy pipelines

Vaxil reports data on P-Esbp-DOX in mouse model of aggressive liver metastasis of colorectal tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...